Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer
The RNA methylation of N6 adenosine (m6A) plays a crucial role in various biological processes. Strong evidence reveals that the dysregulation of long non-coding RNAs (lncRNA) brings about the abnormality of downstream signaling in multiple ways, thus influencing tumor initiation and progression. Cu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Pathology and Oncology Research |
| Subjects: | |
| Online Access: | https://www.por-journal.com/articles/10.3389/pore.2022.1610536/full |
| _version_ | 1827292255245828096 |
|---|---|
| author | Yong Zhang Yong Zhang Lu Li Feifei Chu Xingguo Xiao Li Zhang Kunkun Li Huili Wu |
| author_facet | Yong Zhang Yong Zhang Lu Li Feifei Chu Xingguo Xiao Li Zhang Kunkun Li Huili Wu |
| author_sort | Yong Zhang |
| collection | DOAJ |
| description | The RNA methylation of N6 adenosine (m6A) plays a crucial role in various biological processes. Strong evidence reveals that the dysregulation of long non-coding RNAs (lncRNA) brings about the abnormality of downstream signaling in multiple ways, thus influencing tumor initiation and progression. Currently, it is essential to discover effective and succinct molecular biomarkers for predicting colorectal cancer (CRC) prognosis. However, the prognostic value of m6A-related lncRNAs for CRC remains unclear, especially for progression-free survival (PFS). Here, we screened 24 m6A-related lncRNAs in 622 CRC patients and identified five lncRNAs (SLCO4A1-AS1, MELTF-AS1, SH3PXD2A-AS1, H19 and PCAT6) associated with patient PFS. Compared to normal samples, their expression was up-regulated in CRC tumors from TCGA dataset, which was validated in 55 CRC patients from our in-house cohort. We established an m6A-Lnc signature for predicting patient PFS, which was an independent prognostic factor by classification analysis of clinicopathologic features. Moreover, the signature was validated in 1,077 patients from six independent datasets (GSE17538, GSE39582, GSE33113, GSE31595, GSE29621, and GSE17536), and it showed better performance than three known lncRNA signatures for predicting PFS. In summary, our study demonstrates that the m6A-Lnc signature is a promising biomarker for forecasting patient PFS in CRC. |
| first_indexed | 2024-04-24T12:58:56Z |
| format | Article |
| id | doaj.art-b38e15dac5db411bb1d59db813ca1707 |
| institution | Directory Open Access Journal |
| issn | 1532-2807 |
| language | English |
| last_indexed | 2024-04-24T12:58:56Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Pathology and Oncology Research |
| spelling | doaj.art-b38e15dac5db411bb1d59db813ca17072024-04-05T16:23:29ZengFrontiers Media S.A.Pathology and Oncology Research1532-28072022-08-012810.3389/pore.2022.16105361610536Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal CancerYong Zhang0Yong Zhang1Lu Li2Feifei Chu3Xingguo Xiao4Li Zhang5Kunkun Li6Huili Wu7Department of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, ChinaBranch Center of Advanced Medical Research Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, ChinaDepartment of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, ChinaDepartment of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, ChinaDepartment of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, ChinaDepartment of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, ChinaDepartment of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, ChinaDepartment of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, ChinaThe RNA methylation of N6 adenosine (m6A) plays a crucial role in various biological processes. Strong evidence reveals that the dysregulation of long non-coding RNAs (lncRNA) brings about the abnormality of downstream signaling in multiple ways, thus influencing tumor initiation and progression. Currently, it is essential to discover effective and succinct molecular biomarkers for predicting colorectal cancer (CRC) prognosis. However, the prognostic value of m6A-related lncRNAs for CRC remains unclear, especially for progression-free survival (PFS). Here, we screened 24 m6A-related lncRNAs in 622 CRC patients and identified five lncRNAs (SLCO4A1-AS1, MELTF-AS1, SH3PXD2A-AS1, H19 and PCAT6) associated with patient PFS. Compared to normal samples, their expression was up-regulated in CRC tumors from TCGA dataset, which was validated in 55 CRC patients from our in-house cohort. We established an m6A-Lnc signature for predicting patient PFS, which was an independent prognostic factor by classification analysis of clinicopathologic features. Moreover, the signature was validated in 1,077 patients from six independent datasets (GSE17538, GSE39582, GSE33113, GSE31595, GSE29621, and GSE17536), and it showed better performance than three known lncRNA signatures for predicting PFS. In summary, our study demonstrates that the m6A-Lnc signature is a promising biomarker for forecasting patient PFS in CRC.https://www.por-journal.com/articles/10.3389/pore.2022.1610536/fullcolorectal cancerlncRNAsignaturem6Aprogression free survival |
| spellingShingle | Yong Zhang Yong Zhang Lu Li Feifei Chu Xingguo Xiao Li Zhang Kunkun Li Huili Wu Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer Pathology and Oncology Research colorectal cancer lncRNA signature m6A progression free survival |
| title | Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer |
| title_full | Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer |
| title_fullStr | Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer |
| title_full_unstemmed | Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer |
| title_short | Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer |
| title_sort | identification and validation of an m6a related lncrna signature to predict progression free survival in colorectal cancer |
| topic | colorectal cancer lncRNA signature m6A progression free survival |
| url | https://www.por-journal.com/articles/10.3389/pore.2022.1610536/full |
| work_keys_str_mv | AT yongzhang identificationandvalidationofanm6arelatedlncrnasignaturetopredictprogressionfreesurvivalincolorectalcancer AT yongzhang identificationandvalidationofanm6arelatedlncrnasignaturetopredictprogressionfreesurvivalincolorectalcancer AT luli identificationandvalidationofanm6arelatedlncrnasignaturetopredictprogressionfreesurvivalincolorectalcancer AT feifeichu identificationandvalidationofanm6arelatedlncrnasignaturetopredictprogressionfreesurvivalincolorectalcancer AT xingguoxiao identificationandvalidationofanm6arelatedlncrnasignaturetopredictprogressionfreesurvivalincolorectalcancer AT lizhang identificationandvalidationofanm6arelatedlncrnasignaturetopredictprogressionfreesurvivalincolorectalcancer AT kunkunli identificationandvalidationofanm6arelatedlncrnasignaturetopredictprogressionfreesurvivalincolorectalcancer AT huiliwu identificationandvalidationofanm6arelatedlncrnasignaturetopredictprogressionfreesurvivalincolorectalcancer |